<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04496596</url>
  </required_header>
  <id_info>
    <org_study_id>RLS003-02-001</org_study_id>
    <nct_id>NCT04496596</nct_id>
  </id_info>
  <brief_title>Study of Suramin in Subjects With Furosemide-Resistant AKI</brief_title>
  <official_title>A Prospective, Double-Blind, Placebo-controlled Study of Suramin in Subjects With Furosemide-Resistant Acute Kidney Injury (AKI): Efficacy in Preventing Dialysis Dependent AKI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rediscovery Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rediscovery Life Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, double-blind, randomized, placebo-controlled study to assess the&#xD;
      effects of suramin as a potential treatment option to prevent subjects with AKI from&#xD;
      progressing to Kidney Disease Improving Global Outcomes (KDIGO) Stage III or dialysis&#xD;
      dependent AKI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 13, 2020</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">November 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate and compare the efficacy of a single 3.0 mg/kg infusion of suramin versus placebo in subjects with diuretic unresponsive AKI</measure>
    <time_frame>7 days</time_frame>
    <description>The difference between the effect of a 3.0 mg/kg infusion of suramin versus placebo will be based on meeting 2 or more of the composite event endpoints of: peak serum creatinine (Cr) of 6 mg/dL or above from investigational product (IP) infusion through Day or progression to KDIGO Stage III within 72 hours (hr) from IP infusion or death or dialysis from IP infusion through Day 7.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Acute Kidney Injury</condition>
  <arm_group>
    <arm_group_label>Suramin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Suramin</intervention_name>
    <description>Suramin is administered via IV infusion as a single dose of 3 mg/kg</description>
    <arm_group_label>Suramin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 18 years of age at the time of signing the informed consent&#xD;
&#xD;
          -  KDIGO Stage I AKI and a serum Cr increase ≥ 0.3 mg/dL within 48 hr or 1.5 to 1.9-times&#xD;
             baseline (pre-FST) Cr levels within 48 hr (± 6 hr) prior to randomization OR KDIGO&#xD;
             Stage II AKI and serum Cr increase 2.0 to 2.9-times baseline (pre-FST) Cr levels&#xD;
             within 48 hr (± 6 hr) prior to randomization&#xD;
&#xD;
          -  Fails to achieve a 200 mL increase in urine output within 2 hr following a 1.0 mg/kg&#xD;
             bolus of furosemide (i.e., positive FST)&#xD;
&#xD;
          -  If female of childbearing potential, must have a negative pregnancy test at Screening&#xD;
             Is capable of providing informed consent as described in in this protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receiving hemodialysis or peritoneal dialysis&#xD;
&#xD;
          -  Prior renal transplant (other organ transplants are not excluded)&#xD;
&#xD;
          -  Known baseline (pre-FST) estimated glomerular filtration rate (eGFR) ≤ 20 mL/min&#xD;
&#xD;
          -  Evidence of hydronephrosis or obstructive uropathy confirmed by renal ultrasound (for&#xD;
             subjects without a documented ultrasound, the&#xD;
&#xD;
          -  Investigator will determine if a renal ultrasound is indicated, consistent with the&#xD;
             standard of care (SOC)&#xD;
&#xD;
          -  Hepatic encephalopathy, Child class C cirrhosis, and/or clinical suspicion of&#xD;
             hepatorenal syndrome&#xD;
&#xD;
          -  International normalized ratio (INR) ≤ 3.0, unless on stable long-term warfarin&#xD;
             therapy within 2 weeks prior to randomization&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV), hepatitis B or hepatitis C infection&#xD;
&#xD;
          -  Known coronavirus (COVID-19) infection&#xD;
&#xD;
          -  White blood cell count (WBC) &lt; 2,000/μL and/or platelet count &lt; 30,000/μL at the time&#xD;
             of Screening&#xD;
&#xD;
          -  A sequential organ failure assessment (SOFA) score &gt; 10 during Screening&#xD;
&#xD;
          -  Subjects requiring 3 or more vasopressor agents of any combination to maintain a mean&#xD;
             arterial pressure &gt; 65 mm Hg&#xD;
&#xD;
          -  Unwilling to participate in follow-up phone surveys up to 180 days post-treatment&#xD;
&#xD;
          -  Are enrolled in another interventional research study or have participated in another&#xD;
             interventional study within 14 days of Screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jeremy Whitson</last_name>
    <phone>423-943-4265</phone>
    <email>Jwhitson@nephrosynergy.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Baylor Scott and White Research Institute - Dallas Clinical Trials Office</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harold Szerlip, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>July 29, 2020</study_first_submitted>
  <study_first_submitted_qc>July 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 3, 2020</study_first_posted>
  <last_update_submitted>March 14, 2021</last_update_submitted>
  <last_update_submitted_qc>March 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Suramin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

